CA
TBPH icon

Cliff Asness’s Theravance Biopharma TBPH Stock Holding History

Cliff Asness’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$813K Buy
47,820
+20,463
+75% +$339K ﹤0.01% 3123
2026
Q1 		$444K Buy
27,357
+2,673
+11% +$47.3K ﹤0.01% 3193
2025
Q4 		$462K Buy
24,684
+5,849
+31% +$97K ﹤0.01% 2953
2025
Q3 		$275K Buy
18,835
+6,586
+54% +$83.2K ﹤0.01% 3123
2025
Q2 		$135K Buy
12,249
+979
+9% +$9.52K ﹤0.01% 3131
2025
Q1 		$101K Buy
+11,270
New +$105K ﹤0.01% 3015
2015
Q1 		– Sell
-15,236
Closed -$227K – 2306
2014
Q4 		$227K Buy
+15,236
New +$265K ﹤0.01% 2319

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Cliff Asness's TBPH Position: Q2 2026 in Review

Cliff Asness increased its Theravance Biopharma (TBPH) stake by 75% in Q2 2026, buying an estimated $339K and bringing the position to 47,820 shares worth $813K. The position accounts for ﹤0.01% of the portfolio, ranked #3123.

Cliff Asness first reported a position in TBPH in Q4 2014 and has held it in 7 quarters since. 178 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Cliff Asness held 47,820 shares of Theravance Biopharma worth $813K as of Q2 2026.
  • Cliff Asness bought 20,463 Theravance Biopharma shares in Q2 2026, an estimated $339K.
  • Theravance Biopharma made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #3123 holding.
  • Cliff Asness first reported a position in Theravance Biopharma in Q4 2014 and has held it in 7 quarters since.
  • 178 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.